title: Clinical inquiries. Does warfarin prevent venous thromboembolic events in aPL-positive patients?
authors.affiliation: Waukesha Family Medicine Residency Program, Waukesha, USA.
authors.forename: Michael F
authors.initials: MF
authors.lastname: Mazzone
authors.forename: Barbara
authors.initials: B
authors.lastname: Jamieson
authors.forename: Vincent
authors.initials: V
authors.lastname: Lo
mesh_terms: D000328:Adult; D000367:Age Factors; D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005194:Family Practice; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D017152:Antibodies, Antiphospholipid; D014859:Warfarin